BusinessIndependent Data Monitoring Committee Recommends Continuation of CytoDyn’s PRO 140 Pivotal Combination Therapy Trial as Planned Without Modifications to Achieve Primary EndpointBy Nasdaq OMXDec 7, 2017, 11:00 AM UTC
BusinessMyriad Genetics Presents Pivotal Validation Study for New riskScore™ Test at the 2017 San Antonio Breast Cancer SymposiumBy Nasdaq OMXDec 6, 2017, 11:00 PM UTC
BusinessNetworkNewsWire Announces Publication featuring Advances in Cannabinoid Products and Therapies for Pain ManagementBy Nasdaq OMXDec 6, 2017, 1:30 PM UTC
BusinessFrom Trash to Tank: Upcycling of Landfill to Fuel Demonstrated in JapanBy Nasdaq OMXDec 6, 2017, 1:01 PM UTC
BusinessAxsome Therapeutics Announces Closing of $9.5 Million Registered Direct OfferingBy Nasdaq OMXDec 6, 2017, 12:00 PM UTC
BusinessMacroGenics Announces Closing of MGA012 Global Collaboration and License Agreement with IncyteBy Nasdaq OMXDec 5, 2017, 9:30 PM UTC
BusinessRedHill Biopharma Provides 2017 Year-End Business UpdateBy Nasdaq OMXDec 5, 2017, 2:30 PM UTC
BusinessAdverum Biotechnologies Begins Patient Enrollment in the ADVANCE Phase 1/2 Clinical Trial for A1AT DeficiencyBy Nasdaq OMXDec 5, 2017, 2:02 PM UTC
